BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai Henlius Biotech readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai Henlius Biotech's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06839066-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:HLX43: Phase 2 readout est. (NCT06839066)
DESCRIPTION:HLX43\, phase 2.\nStudy: A Phase II Study to Evaluate HLX43 in 
 Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Into
 lerance to Second-line Therapy\nEstimated primary completion: 22 November 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06839066
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459738-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43: Phase 2 readout est. (NCT07459738)
DESCRIPTION:HLX43\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy: A
  Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients W
 ith Hormone Receptor Positive\, HER2 Negative Locally Advanced or Metastat
 ic Breast Cancer\nEstimated primary completion: 30 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07459738
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106892-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43: Phase 2 readout est. (NCT07106892)
DESCRIPTION:HLX43\, phase 2.\nStudy: Phase II\, Open-label\, Multicenter St
 udy to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Su
 bjects With Advanced Colorectal Cancer\nEstimated primary completion: 30 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07106
 892
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769152-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HLX43: Phase 2 readout est. (NCT06769152)
DESCRIPTION:HLX43\, phase 2.\nStudy: A Phase II Clinical Study to Evaluate 
 the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advance
 d Gynecological Malignant Tumors\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06769152
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487519-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:HLX43: Phase 2 readout est. (NCT07487519)
DESCRIPTION:HLX43\, phase 2.\nStudy: Phase II Study of HLX43 Monotherapy or
  Combined With Immune Checkpoint Inhibitors in Patients With Locally Advan
 ced\, Recurrent\, or Metastatic Triple-negative Breast Cancer.\nEstimated 
 primary completion: 15 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/hlx43#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07487519
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:HLX43: Phase 2 readout est. (NCT07253142)
DESCRIPTION:HLX43\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subj
 ects With Advanced Lung Cancer\nEstimated primary completion: 18 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07253142
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895512-3168@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HLX15: Phase 3 readout est. (NCT06895512)
DESCRIPTION:HLX15\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evaluate
  the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with
  Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Ne
 wly Diagnosed Multiple Myeloma\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/hlx15#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06895512
URL:https://assetmemo.bio/drug/hlx15#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358585-1999@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Pimurutamab: Phase 1/2 readout est. (NCT07358585)
DESCRIPTION:Pimurutamab\, phase 1/2.\nStudy: A Phase Ib/II Study to Evaluat
 e HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Me
 tastatic Colorectal Cancer\nEstimated primary completion: 28 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pimurutamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07358585
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115485-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:HLX43: Phase 2 readout est. (NCT07115485)
DESCRIPTION:HLX43\, phase 2.\nStudy: Phase II\, Open-label\, Multicenter St
 udy to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Su
 bjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma\n
 Estimated primary completion: 30 August 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/hlx43#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07115485
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857279-1999@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pimurutamab: Phase 2 readout est. (NCT06857279)
DESCRIPTION:Pimurutamab\, phase 2.\nStudy: A Phase II Clinical Study to Eva
 luate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamou
 s Cell Carcinoma\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pimurutamab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06857279
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07301229-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20280221
DTEND;VALUE=DATE:20280222
SUMMARY:HLX43: Phase 2 readout est. (NCT07301229)
DESCRIPTION:HLX43\, phase 2.\nStudy: A Phase II Clinical Study to Evaluate 
 HLX43 in Subjects With Advanced Pancreatic Cancer\nEstimated primary compl
 etion: 21 February 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/hlx43#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07301229
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06907615-2039@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:HLX43: Phase 2 readout est. (NCT06907615)
DESCRIPTION:HLX43\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cel
 l Lung Cancer (NSCLC)\nEstimated primary completion: 20 April 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06907615
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459751-1999@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20300115
DTEND;VALUE=DATE:20300116
SUMMARY:Pimurutamab: Phase 2/3 readout est. (NCT07459751)
DESCRIPTION:Pimurutamab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of
  HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in 
 Advanced or Metastatic Squamous Non-Small Cell Lung Cancer\nEstimated prim
 ary completion: 15 January 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pimurutamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07459751
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-1999@assetmemo.bio
DTSTAMP:20261121T005942Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Pimurutamab: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Pimurutamab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplul
 imab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pe
 mbrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous 
 Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pimurutamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
